Menopausal Hormone Therapy Positively Linked to Dementia
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
FRIDAY, June 30, 2023 -- Menopausal hormone therapy is positively associated with all-cause dementia, even in women receiving treatment at age 55 years or younger, according to a study published online June 28 in The BMJ.
Nelsan Pourhadi, M.D., from Copenhagen University Hospital-Rigshospitalet in Denmark, and colleagues conducted a nationwide, nested case-control study involving 5,589 incident cases of dementia and 55,890 age-matched controls identified between 2000 and 2018 from a population of all Danish women to examine the association between use of menopausal hormone therapy and development of dementia.
The researchers found that people who had received estrogen-progestogen therapy had an increased rate of all-cause dementia compared with those who had never used treatment (hazard ratio, 1.24). Higher hazard ratios were seen with increasing durations of use, ranging from 1.21 to 1.72 for one year or less and for more than 12 years, respectively. For both continuous and cyclic regimens, estrogen-progestogen therapy was positively associated with development of dementia (hazard ratios, 1.31 and 1.24, respectively). In women who received treatment at age 55 years or younger, the associations persisted (hazard ratio, 1.24). When restricted to late-onset dementia and Alzheimer disease, the findings persisted (hazard ratios, 1.21 and 1.22, respectively).
"Further studies are warranted to explore if the observed association in this study between menopausal hormone therapy use and increased risk of dementia illustrates a causal effect," the authors write.
Several authors disclosed ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted June 2023
Read this next
Fezolinetant Safe, Effective for Moderate-to-Severe Menopause Hot Flashes
MONDAY, May 20, 2024 -- Fezolinetant is safe and effective for moderate-to-severe vasomotor symptoms (VMS), according to a study presented at the annual European Congress of...
Half of Native Americans Older Than 70 Years May Have Cognitive Impairment
FRIDAY, May 17, 2024 -- More than half of Native Americans aged 70 years and older have cognitive impairment, according to a study published online May 15 in Alzheimer's...
Individual Ability to Be Mobile in Community Tied to Cognitive Function
WEDNESDAY, May 15, 2024 -- Community mobility is significantly associated with cognitive function in older adults, according to a study published online May 15 in the Journal...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.